Glyciome’s Research & Development

Our Cervical Cancer Prevention Technology

Our lead break-through prebiotic personal lubricant "PreBioGyn" is being developed to optimize genital health to reduce disruptions of the genital ecosystem that increase cervical cancer and genital infection risks, especially for people in low resource settings (LRS) with poor healthcare access. These people are those most at risk of developing cervical cancer, the 4th most frequent female cancer worldwide, and a U.S. demographic currently experiencing a “staggering rise” in death rates from this cancer.

Glyciome's prebiotic technology is supported by federal and regional funding awarded across multiple development phases. Our NCI Phase I STTR “Cervical Cancer Prevention Prebiotic Device” was completed in late 2023, and funded under NOT-CA-21-062 (Cancer Prevention, Diagnosis, and Treatment Technologies for Low- Resource Settings). The program is now advancing under an NCI Phase II STTR (NIH/NCI SBIR-STTR, 2025 to 2028; grant number 2 R44 CA254543-02A1). In 2022, Glyciome participated in I-Corps at NIH-NCI, an NIH entrepreneurship training program for active SBIR/STTR Phase I awardees (PAR-22-073), which informed the company's commercialization strategy. Glyciome has also received funding from the Health Sciences and Services Authority (HSSA) of Spokane County for development of this first-in-class prebiotic lubricant, which received its first issued US patent in 2024, with continued patent issuance and filing in 2025. This federally and regionally funded research is conducted in collaboration with leading genital microbiome experts across the United States and has resulted in peer-reviewed presentations and published abstracts(1-4).

Glyciome Cervical Cancer Prevention Technology
Glyciome Cervical Cancer Prevention Technology

Our Related Technology Pipeline

  • Our direct-to-consumer (DTC) Wild & Pure® prebiotic, total-body cleansers (wildandpure.com) are used for skin and genital care across all ages. Wild & Pure* won the 2021 Idaho Innovation Award for Consumer Product of the Year. Our ‘Natural’ version is EWG-verified® which assure consumers of the rigorous scientific review these products have undergone to meet the highest standards in safety.
  • Our near-market, kraft-paper vaginal applicator was developed during Phase I for PreBioGyn gel delivery and decreases waste and plastic contaminant exposure during gel application.
  • Our translational-stage related mobile app will monitor vaginal health and increase product-fit awareness for patients and providers during use of PreBioGyn and other vaginal products.
  • Our early-stage, carbon nanotube biosensor is a rapid, user-directed diagnostic screen for bacterial vaginosis (BV), the most common of all vaginal infections. Glyciome is uniquely positioned to revolutionize global health – including women’s health, and grow bioscience business jobs in Spokane through commercialization of our disruptive technologies. Completed PreBioGyn Phase I STTR studies provided significant de-risking and feasibility support for commercialization of our cervical cancer prevention gel.

Footnotes

1. Ellington J, Clifton GD, Ellington-Lawrence RD, Zamora De la Fuente V, Fichorova R. A Prebiotic Hydrogel to Prevent Cervical Cancer by Optimizing the Vaginal Ecology and Reducing Oncogenic Biological Risk Factors in Women Across Global Health Care Access. JCO Global Oncology 2022;8(Suppl_NCI1):38. DOI: 10.1200/GO.22.44000

2. Richorova RN, Lewis J, Clifton GD, Ellington J. Biocompatibility of a Novel Prebiotic Vaginal Gel for Treating the Underlying Conditions of Vaginal Dysbiosis and Inflammation That Facilitate Cervical Cancer Formation and Progression. JCO Global Oncology 2024;10(Suppl_NCI1):29. DOI: 10.1200/GO-24-27000

3. Clifton D, Fichorova R, Feldman S, Romaguera J, Godoy-Vitorino F, Fremlin J, Ellington-Lawrence R, Carey V, Pena N, Diaz J, Stokes E, Ellington J. Novel, Plastic-Free Vaginal Applicator for Reduction of Environmental and Systemic Plastic Chemical Exposures That Associate With Cancers. JCO Global Oncology 2024;10(Suppl_NCI1):135. DOI: 10.1200/GO-24-11100

4. Ellington J, Clifton D, Fremlin J, Stokes E, Shuster J. Regional College Women in the United States (U.S.) Report Low Health Literacy Regarding Basic Genital Biology and Cervical Cancer Risk Factors. Cancer Epidemiology, Biomarkers and Prevention 2023;32(6_Suppl):Abstract 71. Proceedings of the 11th Annual Symposium on Global Cancer Research, AACR, April 4 to 6, 2023, Philadelphia, PA. DOI: 10.1158/1538-7755.ASGCR23-Abstract-71